ALK‐positive lung cancer in a patient with recurrent brain metastases and meningeal dissemination who achieved long‐term survival of more than seven years with sequential treatment of five ALK‐inhibitors: A case report

The incidence of central nervous system (CNS) metastases in patients with anaplastic lymphoma kinase (ALK) fusion gene‐positive (ALK+) non‐small cell lung cancer (NSCLC) is high, ranging from approximately 20%–70%. Although ALK inhibitors (ALKis) are generally effective for CNS metastases in patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Keisuke, Toyokawa, Gouji, Kozuma, Yuka, Shoji, Fumihiro, Yamazaki, Koji, Takeo, Sadanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169298/
https://www.ncbi.nlm.nih.gov/pubmed/33939293
http://dx.doi.org/10.1111/1759-7714.13962

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169298/
https://www.ncbi.nlm.nih.gov/pubmed/33939293
http://dx.doi.org/10.1111/1759-7714.13962

Ejemplares similares